Background: To evaluate the prevalence of upper gastrointestinal (GI) polyps in familial adenomatous polyposis (FAP), and to discuss current therapeutic recommendations. Methods: Clinical, endoscopic, histological and treatment data were retrieved from charts of 102 patients . Duodenal adenomatosis was classified according to Spigelman stages.
Introduction
Familial adenomatous polyposis (FAP) is a complex hereditary syndrome which most conspicuous feature is the development of multiple colorectal polyps and a diverse variety of benign and malignant extracolonic manifestations (ECM). Among these ECM, the coexistence of extracolonic polyps has been known for over 100 years after the description in the stomach by Hauser in 1895 (1) and in the duodenum by Funkenstein in 1904 (2) .
In FAP, upper digestive lesions include gastric fundic gland polyps (FGP), antrum adenomas, duodenal or small
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Upper gastrointestinal neoplasia in familial adenomatous polyposis: prevalence, endoscopic features and management intestinal adenomas and carcinoma. The duodenum is considered the second most common site of polyps after the colorectum (3, 4) . In this segment, lifetime risks of adenoma and adenocarcinoma approach 100% and 3-5%, respectively. The cumulative cancer incidence was estimated as 18% at 75 years of age (5) . Compared to the general population (in which duodenal cancer is rare), the relative risks of duodenal malignancy and ampullary carcinoma are 331 and 124 times greater, respectively (6) .
During the 1990s, some important publications addressed the incidence and risk factors associated with malignant degeneration in the upper digestive tract (7) (8) (9) . At the same time, attempts to identify a genotype-phenotype relationship have been inconsistent (3) . Consequently, the upper gastrointestinal (GI) tract has been considered a segment that deserves regular endoscopic surveillance, although the optimal criteria for either endoscopic examinations or management have not yet been fully determined.
Over the years, upper digestive findings in FAP patients have been more critically evaluated as they are considered an important cause of morbidity and mortality. An active search for jejunal lesions has been rarely performed in these patients; moreover, descriptive reports in our country are scarce (10, 11) . Therefore, the aim of the present study was to evaluate the prevalence of upper digestive lesions (including the stomach, duodenum and jejunum) in FAP patients who were treated and followed in a tertiary public hospital in the last decades. Moreover, we report the results of endoscopic or surgical resection of advanced lesions, reviewing current recommendations for surveillance and management.
Methods
The study was approved by the Gastroenterology Department Ethics Committee approved the present study (Memo-CAPPesq 049/17). Charts from 140 FAP patients treated in the Colorectal Unit during the last 58 years (from July 1958 to December 2017) were reviewed, focusing on those who underwent upper digestive endoscopic evaluation. Patients who underwent endoscopic examinations signed an informed consent on the aims and morbidity of the procedure.
There were collected clinical (gender, age, family history of FAP and gastroduodenal cancer), endoscopic (age at examination, lesion number, location and histology) and management data (simple biopsy, endoscopic resection/ surgical treatment, evolution while on endoscopic surveillance, complications of endoscopic or surgical therapy). This information was retrieved from retrospective ] and prospective (after 1998) collected data, when patients started to undergo prospective upper digestive surveillance.
All patients underwent esophagogastroduodenoscopy (EGD) with front-view and/or side-view endoscopes. Examinations were performed with a Fujinon ED 250XT or Olympus JF-130. A small group of patients were also submitted to balloon enteroscopy with a Fujinon EN 450P5 enteroscope.
The location, number, gross appearance and sizes of the polyps or lesions were retrieved. Histological data were derived from tissue extracted from suspected lesion samples or endoscopic/surgical resected specimens, and duodenal adenomatosis was classified according to Spigelman stages, the most used risk-stratification for duodenal cancer (12) . Advanced ampullary or duodenal tumors (lesions greater than 10 mm with villous histology and high-grade dysplasia) were also assessed by endoscopic ultrasound (EUS) prior to endoscopic resection to carefully evaluate the dimensions, chances of polypectomy or need for subsequent surgical resection. Figure 1) were the most common lesions diagnosed with upper endoscopy ( Table 2 ). While 5 adenomas were found in the stomach, 33 patients presented with duodenal or ampullary adenomas (Figures 2,3) . Advanced lesions (lesions larger than 10 mm in diameter with high-grade dysplasia, villous or tubule-villous morphology, or any combination of the above features) were detected in the stomach (n=2) and duodenum (n=11).
Results

During
Carcinomas were diagnosed in the stomach (n=4) and duodenum (n=4). Gastric malignancy was diagnosed at 44, 48, 51 and 58 years. Duodenal carcinomas were detected at a mean age of 55.0 years (range, 50-64 years). One patient was diagnosed with stage IV disease at the time of proctocolectomy to resect a CRC and developed an intramucosal carcinoma 1.5 years later. The other three carcinomas were detected during follow-up in patients without previous endoscopy.
The results regarding duodenal findings are listed in Table 3 . Patients at Spigelman 0 stage were predominant at both the first and last endoscopy. Except in stage IV patients, the incidence of more advanced stages progressed over time. The incidence of duodenal carcinoma was greater in the second group. The comparison of duodenal severity between the first and last endoscopies revealed that the Spigelman stage improved in 6 (12.2%) patients, remained unchanged in 25 (51.0%) and worsened in 18 (36.7%).
A subgroup of 21 patients was also evaluated by enteroscopy. The enteroscope was advanced through median extension of 134 cm (60 to 200 cm) after the Treitz ligament, and jejunal adenomas were found in 12 patients. Within this group, duodenal adenomas were also present in 11 patients.
Carcinomas were managed through local resection (endoscopic and surgical), duodenopancreatectomy or gastrectomy ( Table 4) . Therapeutic complications occurred in two patients; one died after duodenopancreatectomy (due to pulmonary complications), and another patient developed bleeding after endoscopic resection of an advanced lesion.
Discussion
Since the 1960s, upper digestive screening and surveillance of polyps in FAP has been increasingly advocated (12, 13) . This idea is based on the almost 100% lifetime risk for duodenal adenomatosis (3, 14, 15) and the cumulative incidences of Spigelman IV and carcinoma (4% to 10%) within this population (16) . Furthermore, duodenal and ampullary malignant tumors are the third most common cause of fatal outcome in FAP patients (17) (18) (19) . Traditionally, duodenal polyps vary significantly in their number and size, appearing like plaque-like lesions. Lowrisk lesions (small, tubular, and low-grade adenomas) may be managed through standard polypectomy, dissection or local ablation techniques, while surgical options are reserved for more advanced lesions (4, 20) . In the present series, duodenal and ampullary adenomas were found in one-third of the patients. These lesions (4, 22) . Another option is the indication of prophylactic surgery for stage IV patients (3, 8, 13) .
Although data on ampullary adenomas are scarce, there is a suggestion that ampullary and duodenal diseases should be considered separately (20, 25) . Ampullary disease deserves an accurate individual risk assessment due to the greater risk of carcinoma compared to nonampullary adenomas, and different surveillance protocols have been proposed with the use of a side-viewing endoscope or chromoendoscopy to improve the detection rates of duodenal polyps (20, 26, 27) .
There is no consensus on the most appropriate surveillance interval following endoscopic resection of ampullary adenomas. As the malignancy risk depends on both ampulla features and staging of the nonampullary duodenal disease, some believe that endoscopic resection may not decrease the need for a more radical operation such as pancreaticoduodenectomy (28, 29) . Nevertheless, there is a consensus that endoscopic surveillance should be performed after 25 years of age with the use of a side or forward viewer endoscope at intervals defined by staging Severe disease has been associated with the time since FAP diagnosis, age and the Spigelman stage at initial endoscopy (37, 38) . Although it is well recognized that duodenal polyposis progresses in severity (size and dysplasia), the transformation into carcinoma tends to be slow in the setting of aggressive and constant management of advanced polyps, preventing malignant transformation (12 In our study, only 8 patients (7.8%) had their last endoscopic examination performed more than 15 years ago.
Moreover, patients with insufficient data were excluded from evaluation. Since our main aim was to evaluate the prevalence of upper GI polyps, there was no difference in the backgrounds concerning the quality of endoscopy, diagnostic criteria and/or staging and therapy strategy.
Decision analysis concerning surgical treatment must be individualized. In this discussion, the morbidity and mortality after local (duodenotomy with polypectomy and/or ampullectomy) or more radical procedures (pancreas and pylorus sparing duodenectomy, cephalic pancreaticoduodenectomy) must be weighed against the risk of duodenal malignancy and clinical status.
Eventually, resection through surgical duodenotomy may be an option in difficult or potentially dangerous cases.
Considering that duodenotomy has a 32-43% recurrence rate (9, 35, 44) and a similar effect on decreasing Spigelman (45, 51, 53, 54) . In the analysis of a group of 66 patients, FGP were found in 43 (65%); 36% were lowgrade and 3% were high-grade dysplasia.
These characteristics imply a potential risk of progression to gastric cancer (21, 55, 56) . Therefore, if FGP have unusual appearances and are greater than 1 cm in size, they should be biopsied or resected.
In our series, 5 gastric adenomas (2 advanced lesions) and 4 gastric carcinomas were also detected. This increased risk of gastric adenomas in FAP has been widely recognized.
The prevalence in the literature ranges from approximately 6-20% in European and American publications (3, 42, 57, 58) . In a recent Japanese publication, Shibata et al. (61) reported that the mean ages at the time of colectomy and gastric cancer diagnosis were 39.2 and 58 years, respectively.
The mean interval between colectomy and gastrectomy was 19 years in five patients. Three out of five patients had multicentric lesions. According to another Japanese series, the incidence of gastric cancer in FAP patients is much greater than in patients without FAP (62) .
There is some evidence that gastric cancer incidence in FAP patients differs between Western and Asian countries, which is commonly attributed to the greater prevalence of gastric cancer in Asia. The reported incidences of gastric cancer in Asian series varied from 2.6% in Japan (63) As patients reach the fifth decade of life, special attention should be given to the development of upper GI cancer. Given the substantial risks associated with duodenal surgical resection, patients considered for surgery deserve a critical preoperative evaluation and selection (47) .
Fortunately, interest regarding the comprehension of risk factors and definition of management guidelines for duodenal polyposis has increased significantly during the last decades (58) . Future efforts should address the development of a more refined staging approach as well as effective strategies for prevention and treatment. In this regard, papilla and duodenal features merit different considerations in an improved staging system. Molecular investigations in this field will probably help categorize the risk groups and indicate prognosis.
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